Sunday, March 16, 2025 | 06:22 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Piramal OTC aims to double turnover to Rs 1,000 cr in three years

PEL's Pharma and financial services arms demerger is expected to be completed over next 3 quarters

Piramal Enterprises
Premium

Photo: Shutterstock

Sohini Das Mumbai
The Nandini Piramal-led over-the-counter (OTC) healthcare business of Piramal Enterprises is not only aiming to double its turnover to Rs 1,000 crore in three years, but now aims to focus more on building a consumer pull for its brands.

Last month Piramal Enterprises (PEL) said that it would demerge its pharma and financial services arm. The demerger is expected to be completed over the next three quarters.

Piramal Pharma, however, draws only 15 per cent of its Rs 5,776 crore revenues from the India business, and bulk comes from North America.

Piramal’s pharma business comprises a contract development and manufacturing

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in